Center-Authored Papers

Filters: Author is Janes, Holly  [Clear All Filters]
2008
Janes H, Pepe MS.  2008.  Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting.. American journal of epidemiology. 168(1):89-97. Abstract
Pepe MS, Janes H.  2008.  Gauging the performance of SNPs, biomarkers, and clinical factors for predicting risk of breast cancer.. Journal of the National Cancer Institute. 100(14):978-9.
Janes H, Pepe MS.  2008.  Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value.. Biometrics. 64(1):1-9. Abstract
Janes H, Pepe MS, Gu W.  2008.  Assessing the value of risk predictions by using risk stratification tables.. Annals of internal medicine. 149(10):751-60. Abstract
McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R et al..  2008.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.. Lancet. 372(9653):1894-905. Abstract
Janes H, Sheppard L, Shepherd K.  2008.  Statistical analysis of air pollution panel studies: an illustration.. Annals of epidemiology. 18(10):792-802. Abstract
Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD.  2008.  Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.. Journal of the National Cancer Institute. 100(20):1432-8. Abstract
2009
Janes H, Longton G, Pepe MS.  2009.  Accommodating Covariates in ROC Analysis.. The Stata journal. 9(1):17-39. Abstract
Pepe MS, Longton G, Janes H.  2009.  Estimation and Comparison of Receiver Operating Characteristic Curves.. The Stata journal. 9(1):1. Abstract
2010
Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG et al..  2010.  Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.. Journal of virology. 84(3):1439-52. Abstract
Janes H, Dominici F, Zeger S.  2010.  On quantifying the magnitude of confounding.. Biostatistics (Oxford, England). 11(3):572-82. Abstract
2011
Janssens CAJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J et al..  2011.  Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.. European journal of epidemiology. 26(4):313-37. Abstract
Pepe MS, Janes H.  2011.  Commentary: Reporting standards are needed for evaluations of risk reclassification.. International journal of epidemiology. 40(4):1106-8.
Janssens CAJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J et al..  2011.  Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration.. Journal of clinical epidemiology. 64(8):e1-e22. Abstract
Janes H, Pepe MS, Bossuyt PM, Barlow WE.  2011.  Measuring the performance of markers for guiding treatment decisions.. Annals of internal medicine. 154(4):253-9. Abstract
Barnabas RV, Wasserheit JN, Huang Y, Janes H, Morrow RA, Fuchs J, Mark KE, Casapia M, Mehrotra DV, Buchbinder SP et al..  2011.  Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study).. Journal of acquired immune deficiency syndromes (1999). 57(3):238-244. Abstract
Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, Gilbert PB, Loufty M, Mehrotra D, Duerr A.  2011.  An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).. The Journal of infectious diseases. 203(6):765-72. Abstract
Janssens CAJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J et al..  2011.  Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.. European journal of human genetics : EJHG. 19(5):18ppreceding494. Abstract
Janssens CAJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J et al..  2011.  Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.. European journal of clinical investigation. 41(9):1010-1035. Abstract
2012
Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP et al..  2012.  MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.. PloS one. 7(8):e43396. Abstract
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86. Abstract
Huang Y, Gilbert PB, Janes H.  2012.  Assessing Treatment-Selection Markers using a Potential Outcomes Framework.. Biometrics. 68(3):687-696. Abstract
2013
Janes H, Pepe M.  2013.  Re: "Clinical Usefulness of the Framingham Cardiovascular Risk Profile beyond Its Statistical Performance: The Tehran Lipid and Glucose Study".. American journal of epidemiology. 177(8):864-5.
Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.  2013.  In Pursuit of an HIV Vaccine: Designing Efficacy Trials in the Context of Partially Effective Non-Vaccine Prevention Modalities.. AIDS research and human retroviruses. Abstract
Janes H.  2013.  Letter to the editor.. Biostatistics (Oxford, England).